5167-18-0

Usage

Uses

Used in Pharmaceutical Industry:
1,7-Dihydro-2-methyl-6-purinone is used as a potential drug candidate for the treatment of inflammatory and pain-related conditions due to its anti-inflammatory and analgesic properties.
Used in Materials Science:
1,7-Dihydro-2-methyl-6-purinone is used in the development of novel polymers and materials with specific properties, contributing to advancements in various applications within the field of materials science.

InChI:InChI=1/C6H6N4O/c1-3-9-5-4(6(11)10-3)7-2-8-5/h2H,1H3,(H2,7,8,9,10,11)

Upstream product

• 91-22-5 quinoline 
• 5442-02-4 5,6-diamino-2-methylpyrimidin-4(3H)-one sulfate 
• 77287-34-4 formamide 
• 1445-08-5 2-methyl-6-aminopurine 
• 64-18-6 formic acid 
• 117987-01-6 5-(methyl(ethoxy)methylene)-aminoimidazole-4-carboxamide 
• 72-40-2 5-amino-1H-imidazole-4-carboxamide monohydrochloride 
• 141-78-6 ethyl acetate 
• 91026-74-3 5-Acetamidoimidazole-4-carboxamide 
• 45741-61-5 5,6-diamino-2-methylpyrimidin-4(3H)-one 
• 98011-06-4 5-Acetamido-4-amino-2-methylpyrimidine-6-(1H)-one 

Downstream Products

• 38917-31-6 2-methyl-1,7-dihydro-purine-6-thione 
• 100859-35-6 6-chloro-2-methyl-7⁽⁹⁾H-purine 
• 100859-35-6 6-chloro-2-methyl-9H-purine 
• 38917-31-6 2-methyl-1,9-dihydro-purine-6-thione 
• 1008-47-5 2-methyl-6-methylsulfanyl-7(9)H-purine 
• 1026172-67-7 6-Chloro-9-(2-fluoro-benzyl)-2-methyl-9H-purine 

Relevant academic research and scientific papers

Bioisosteric transformations and permutations in the triazolopyrimidine scaffold to identify the minimum pharmacophore required for inhibitory activity against plasmodium falciparum dihydroorotate dehydrogenase

Plasmodium falciparum causes approximately 1 million deaths annually. However, increasing resistance imposes a continuous threat to existing drug therapies. We previously reported a number of potent and selective triazolopyrimidine-based inhibitors of P.

DIHYDROOROTATE DEHYDROGENASE INHIBITORS WITH SELECTIVE ANTI-MALARIAL ACTIVITY

Compounds according to Formula (I), Formula (II), Formula (III), Formula (V), Formula (VI), or to Formula (VII), and pharmaceutical compositions of compounds that conform to Formula (IV) or (Formula VIII): where R1 through R33 are prescribed, selectively inhibit P. falciparum dihydroorotate dehydrogenase. Accordingly, a method for preventing and treating malaria attaches to such compounds, as well as to pharmaceutically acceptable salts, solvates, stereoisomers, tautomers, and prodrugs thereof.

Synthetic studies directed towards agelasine analogs - Synthesis, tautomerism, and alkylation of 2-substituted N-methoxy-9-methyl-9H-purin-6- amines

N-Methoxy-9-methyl-9H-purin-6-amines, carrying various substituents in the 2 positions, were synthesized by the N-methylation of known 6-chloropurines, followed by a displacement of the chlorine. Great variations in the amino/imino tautomer ratio among the compounds studied were observed. The tautomers were identified by NMR methods. Treatment of N-methoxy-9-methyl-9H-purin-6-amines carrying alkyl, alkoxy, or amino substituents in the 2 position with benzyl bromide resulted in a mixture of N-7- and N6-benzylated compounds with the former as the major products. N-Methoxy-9-methyl-9H-purin-6-amines with strongly electronegative substituents at C-2 hardly reacted at all under the same set of reaction conditions. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.

Xanthine oxidase (XO): Relative configuration of complexes formed by the enzyme, 2- or 8-N-alkylhypoxanthines and 2-N-alkyl-8-azahypoxanthines. XII

Several 2- or 8-n-alkyl-hypoxanthines and a 2,8-di-n-pentylhypoxanthine were synthesized and tested as substrates or inhibitors of Xanthine Oxidase (XO). 8-Alkyl derivatives showed a substrate behaviour, whereas 2-alkyl substituted compounds were non-substrates and inhibitors. 2,8-di-n-pentylhypoxanthine was ineffective as inhibitor. The comparison between their activity allowed us to conclude that the complexes formed by the enzyme and the cited n-alkylhypoxanthines or 2-n -alkyl-8-azahypoxanthines involve their N(3) and N(9) positions in all the cases. The position of the n-alkyl chain determines the disposition of the molecule inside the complex: 2-n-alkyl-hypoxanthines and 2-n-alkyl-8-azahypoxanthines gave complexes with the same orientation of heterocyclic moieties, opposite that given by 8-n-alkyl-hypoxanthines.

6-substituted purinyl piperazine derivatives

6-substituted purinyl piperazine derivatives and a method of synthesis for the derivatives are described. The 6-substituted purinyl piperazine derivatives are useful as cardiotonic agents and antiarrhythmic agents.

6-substituted purinyl piperazine derivatives

6-Substituted purinyl piperazine derivatives and a method of synthesis for the derivatives are described. The 6-substituted purinyl piperazine derivatives are useful as cardiotonic agents and antiarrhythmic agents.

SYNTHESIS AND PROPERTIES OF ANALOGS OF 5(4)-AMINOIMIDAZOLE-4(5)-CARBOXAMIDE AND PURINES. ACYLATION OF 5(4)-AMINOIMIDAZOLE DERIVATIVES.

The acylation of 5(4)-aminoimidazole derivatives was studied.It is shown that acylation by means of carboxylic acid anhydrides and chlorides takes place at the amino group, whereas acylation by means of chlorocarbonic acid esters takes place at the nitrogen atoms of the imidazole ring.Methods for the selective introduction of a carbomethoxy group in the 1, 3, and 5 positions of the 5(4)-aminoimidazole-4(5)-carboxamide molecule were developed.